NCT07671963

Brief Summary

This multicenter randomized controlled clinical trial aims to compare the clinical, radiographic, microbiological and molecular outcomes of two collagenated xenogeneic bone substitutes (GTO® and GenOs®) used in combination with the Non-Incised Papilla Surgical Approach (NIPSA) for the treatment of intrabony periodontal defects. The study will evaluate whether differences exist between the two biomaterials with respect to clinical attachment gain, defect resolution, wound healing and biological markers of regeneration.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
7mo left

Started Jul 2026

Shorter than P25 for not_applicable

Geographic Reach
2 countries

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Jul 2026Mar 2027

First Submitted

Initial submission to the registry

June 22, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 26, 2026

Completed
5 days until next milestone

Study Start

First participant enrolled

July 1, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2027

Expected
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

June 26, 2026

Status Verified

June 1, 2026

Enrollment Period

7 months

First QC Date

June 22, 2026

Last Update Submit

June 22, 2026

Conditions

Keywords

periodontitisregenerative treatmentNIPSAbone substitutes

Outcome Measures

Primary Outcomes (1)

  • Clinical Attachment Level (CAL) gain

    Change in clinical attachment level (CAL) at treated intrabony periodontal defects from baseline to 6 months following regenerative periodontal therapy using either GTO® or GenOs® in combination with the Non-Incised Papilla Surgical Approach (NIPSA).

    Baseline to 6 months

Secondary Outcomes (10)

  • Probing Depth (PD) reduction

    Baseline to 6 months

  • Bleeding on Probing (BOP)

    Baseline to 6 months

  • Plaque Index (PI)

    Baseline to 6 months

  • Radiographic bone level changes

    Baseline to 6 months

  • Quantification of periodontal pathogens

    Baseline to 6 months

  • +5 more secondary outcomes

Study Arms (2)

GTO® + NIPSA

EXPERIMENTAL

Regenerative periodontal therapy using GTO® collagenated xenogeneic bone substitute in combination with the Non-Incised Papilla Surgical Approach (NIPSA).

Procedure: GTO® with NIPSA surgical approach

GenOs® + NIPSA

ACTIVE COMPARATOR

Regenerative periodontal therapy using GenOs® collagenated xenogeneic bone substitute in combination with the Non-Incised Papilla Surgical Approach (NIPSA).

Procedure: GenOs® + NIPSA

Interventions

Regenerative periodontal surgical treatment using the Non-Incised Papilla Surgical Approach (NIPSA) combined with GTO® collagenated xenogeneic bone substitute for the treatment of intrabony periodontal defects.

GTO® + NIPSA

Regenerative periodontal surgical treatment using the Non-Incised Papilla Surgical Approach (NIPSA) combined with GenOs® collagenated xenogeneic bone substitute for the treatment of intrabony periodontal defects.

GenOs® + NIPSA

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • Diagnosis of Stage III periodontitis
  • At least one intrabony periodontal defect with probing depth \> 5 mm following completion of non-surgical periodontal therapy
  • Full-mouth plaque score (FMPS) \< 20%
  • Full-mouth bleeding score (FMBS) \< 20%
  • Ability to understand the study procedures and provide written informed consent

You may not qualify if:

  • Systemic medical contraindications to periodontal surgery
  • History of head and neck radiotherapy
  • Poor oral hygiene or lack of motivation/compliance
  • Uncontrolled diabetes mellitus
  • Pregnancy or lactation
  • Treatment with antiresorptive medications or other drugs affecting bone remodeling
  • Heavy smoking (\>20 cigarettes/day)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Department of Periodontology, School of Dental Medicine, University of Cagliari Cittadella Universitaria di Monserrato Monserrato (CA), Italy

Cagliari, Italy, Italy

RECRUITING

Department of Periodontology and Research Implant Center, School of Dental Medicine, University of Belgrade

Belgrade, Serbia

RECRUITING

MeSH Terms

Conditions

Periodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic Diseases

Study Officials

  • Iva Z Milinkovic, DDS, PhD

    School of Dental Medicine, University of Belgrade, Implant Research Centre and Department of Periodontology and Oral Medicine

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Iva Z Milinkovic, DDS, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomly assigned in a 1:1 ratio to receive regenerative periodontal therapy using either GTO® or GenOs® in combination with the Non-Incised Papilla Surgical Approach (NIPSA) for the treatment of intrabony periodontal defects.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 22, 2026

First Posted

June 26, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

February 1, 2027

Study Completion (Estimated)

March 1, 2027

Last Updated

June 26, 2026

Record last verified: 2026-06

Locations